255 related articles for article (PubMed ID: 29032756)
1. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
Mamakou V; Eleftheriadou I; Katsiki N; Makrilakis K; Tsioufis K; Tentolouris N
Curr Vasc Pharmacol; 2017; 16(1):70-78. PubMed ID: 29032756
[TBL] [Abstract][Full Text] [Related]
2. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
4. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
5. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease.
Shen Y; Dai Y; Wang XQ; Zhang RY; Lu L; Ding FH; Shen WF
Cardiovasc Diabetol; 2019 Nov; 18(1):160. PubMed ID: 31733658
[TBL] [Abstract][Full Text] [Related]
6. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
7. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
8. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Lovre D; Htun W; Carrion C; Fonseca VA
Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
[TBL] [Abstract][Full Text] [Related]
9. [Hypertension and diabetes: target blood pressure and blood pressure lowering by new antidiabetic drugs].
Kintscher U; Jacob S
Dtsch Med Wochenschr; 2014 Nov; 139(48):2468-9. PubMed ID: 25409409
[No Abstract] [Full Text] [Related]
10. Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors.
Engeli S; Jordan J
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):468-72. PubMed ID: 24914567
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
13. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
15. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcome trials of glucose-lowering therapies.
Khunti K; Davies MJ; Seidu S
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):237-249. PubMed ID: 32403956
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic drugs and blood pressure changes.
Ilias I; Thomopoulos C; Michalopoulou H; Bazoukis G; Tsioufis C; Makris T
Pharmacol Res; 2020 Nov; 161():105108. PubMed ID: 32738493
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
19. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.
Moyá A; Crespo JJ; Ayala DE; Ríos MT; Pousa L; Callejas PA; Salgado JL; Mojón A; Fernández JR; Hermida RC;
Chronobiol Int; 2013 Mar; 30(1-2):116-31. PubMed ID: 23181613
[TBL] [Abstract][Full Text] [Related]
20. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
